Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR) is remarkable among the hypophosphatemic rickets syndromes for its variable age of presentation and periods of quiescence during which serum phosphate and fibroblast growth factor 23 (FGF 23) levels are normal without therapy. In contrast, hypophosphatemia in X-linked hypophosphatemic rickets (XLH) manifests soon after birth and requires lifelong therapy. This suggests that there are environmental factors which can alter FGF 23 activity in ADHR but not in XLH. We present an adult with ADHR in whom resolution of hypophosphatemia was achieved by correcting iron deficiency without the need for phosphate supplementation. Serial iron and FGF 23 levels revealed an inverse relationship (r=-0.79, p<0.04). All patients with ADHR who present with hypophosphatemia and worsening symptoms should be screened for iron deficiency. If iron deficiency is detected, therapy with a combination of calcitriol and iron supplementation should be considered without phosphate supplementation.

• Authors: Lakshmi P Menon, Robert S Weinstein
• Journal: Bone (Bone) Vol. 131 Pg. 115137 (02 2020) ISSN: 1873-2763 [Electronic] United States
• PMID: 31756522 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• FGF23 protein, human
• Phosphates
• Fibroblast Growth Factors
• Fibroblast Growth Factor-23
• Iron
• Calcitriol

Topics

• Adult
• Calcitriol
• Familial Hypophosphatemic Rickets (complications, drug therapy, genetics)
• Fibroblast Growth Factor-23
• Fibroblast Growth Factors
• Humans
• Hypophosphatemia
• Iron
• Phosphates